PARP inhibitors as maintenance treatment for pancreatic cancer patients with germline BRCA mutations

被引：0
|
作者：
Kawecki, Maciej [1 ]
机构：
[1] Maria Sklodowska Curie Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2019年 / 15卷 / 03期
关键词：
D O I：
10.5603/OCP.2019.0023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：190 / 193
页数：4
相关论文
共 50 条
  • [1] BRCA Mutations and PARP Inhibitors in Breast and/or Ovarian Cancer Patients
    Gari, Abdulrahim
    Rawas, Ghufran
    Mufti, Ahmad
    Elemam, Omima
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND ALLIED SCIENCES, 2021, 10 (03): : 33 - 49
  • [2] Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
    Mukherjee, Shibani
    Asaithamby, Aroumougame
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2154 - 2156
  • [3] PARP inhibitors for hereditary breast cancer with germline BRCA mutation
    Im, Seock-Ah
    ANNALS OF ONCOLOGY, 2022, 33 : S423 - S423
  • [4] The role of PARP inhibitors in BRCA mutated pancreatic cancer
    Chi, Jeffrey
    Chung, Su Yun
    Parakrama, Ruwan
    Fayyaz, Fatima
    Jose, Jyothi
    Saif, Muhammad Wasif
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [5] The Role of PARP Inhibitors in Germline BRCA-Associated Pancreatic Ductal Adenocarcinoma
    Moffat, Gordon T.
    O'Reilly, Eileen M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (03) : 168 - +
  • [6] BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
    Ferrone, Cristina R.
    Levine, Douglas A.
    Tang, Laura H.
    Allen, Peter J.
    Jarnagin, William
    Brennan, Murray F.
    Offit, Kenneth
    Robson, Mark E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) : 433 - 438
  • [7] Absence of germline BRCA1 mutations in familial pancreatic cancer patients
    Axilbund, Jennifer E.
    Argani, Pedram
    Kamiyama, Mihoko
    Palmisano, Emily
    Raben, Marian
    Borges, Michael
    Brune, Kieran A.
    Goggins, Michael
    Hruban, Ralph H.
    Klein, Alison P.
    CANCER BIOLOGY & THERAPY, 2009, 8 (02) : 131 - 135
  • [8] BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
    Petrelli, Annalisa
    Rizzolio, Sabrina
    Pietrantonio, Filippo
    Bellomo, Sara E.
    Benelli, Matteo
    De Cecco, Loris
    Romagnoli, Dario
    Berrino, Enrico
    Orru, Claudia
    Ribisi, Salvatore
    Moya-Rull, Daniel
    Migliore, Cristina
    Conticelli, Daniela
    Maina, Irene M.
    Puliga, Elisabetta
    Serra, Violeta
    Pellegrino, Benedetta
    Llop-Guevara, Alba
    Musolino, Antonino
    Siena, Salvatore
    Sartore-Bianchi, Andrea
    Prisciandaro, Michele
    Morano, Federica
    Antista, Maria
    Fumagalli, Uberto
    De Manzoni, Giovanni
    Degiuli, Maurizio
    Baiocchi, Gian Luca
    Amisano, Marco F.
    Ferrero, Alessandro
    Marchio, Caterina
    Corso, Simona
    Giordano, Silvia
    CANCER RESEARCH, 2023, 83 (10) : 1699 - 1710
  • [9] PARP-Inhibitors in BRCA-Associated Pancreatic Cancer
    Bhalla, Anshul
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2014, 15 (04): : 340 - 343
  • [10] Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting
    Stossel, Chani
    Raitses-Gurevich, Maria
    Atias, Dikla
    Beller, Tamar
    Gorman, Yulia Glick
    Halperin, Sharon
    Peer, Eyal
    Denroche, Robert E.
    Zhang, Amy
    Notta, Faiyaz
    Wilson, Julie M.
    O'Kane, Grainne M.
    Talmoud, Elina Haimov
    Amison, Nora
    Schvimer, Michael
    Salpeter, Seth J.
    Bar, Vered
    Zundelevich, Adi
    Tirosh, Itay
    Tal, Rotem
    Dinstag, Gal
    Kinar, Yaron
    Eliezer, Yonatan
    Ben-David, Uri
    Gavert, Nancy S.
    Straussman, Ravid
    Gallinger, Steven J.
    Berger, Raanan
    Golan, Talia
    CANCER DISCOVERY, 2023, 13 (08) : 1826 - 1843
12345